Cell Therapy & Immunoengineering Program

Transforming therapeutics through discovery

The Cell Therapy and Immuno-Engineering Program (CTIP) advances next-generation cell therapies through mechanistic discovery, translational research and clinical development. Working with clinicians, surgeons and scientists at Cleveland Clinic and collaborating institutions, we study why current therapies succeed or fail, develop safer and more effective approaches, and translate those discoveries into early-phase clinical trials.

More About Us

What is CAR T-cell therapy?

Some cancers evade recognition by the immune system. Chimeric antigen receptor (CAR) T-cell therapy is a personalized form of immunotherapy in which a patient's T cells are genetically reprogrammed to recognize and attack a specific target on cancer cells.

More about CAR T-cell Therapy

Cell Therapy researchers collaborate with clinicians at the nearby Taussig Cancer Institute, who work to treat some of the most complex cancer cases. Our method of research allows scientists to more safely and effectively target cancers in patients receiving care just around the corner.

Discovery and collaboration are at the heart of our work, with interdisciplinary teams working together to build mechanistic insight and therapeutic innovation.

What makes us unique

Focus Areas

Cell therapy
CAR T cells
Genomic therapy
Immunotherapy

Cell Therapy & Immunoengineering Program

Transforming therapeutics through discovery

What is CAR T-cell therapy?

Focus Areas

Why Cell Therapy is effective in attacking disease